These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 30380060)
21. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects. Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131 [TBL] [Abstract][Full Text] [Related]
22. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience. Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Canut A; Isla A; Rodríguez-Gascón A Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia. García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362 [TBL] [Abstract][Full Text] [Related]
25. A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators. Cristinacce A; Wright JG; Stone GG; Hammond J; McFadyen L; Raber S Infect Dis Ther; 2019 Jun; 8(2):185-198. PubMed ID: 30963520 [TBL] [Abstract][Full Text] [Related]
26. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Esposito S; Carrothers TJ; Riccobene T; Stone GG; Kantecki M Paediatr Drugs; 2021 Nov; 23(6):549-563. PubMed ID: 34462863 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Werth BJ; Barber KE; Ireland CE; Rybak MJ Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016 [TBL] [Abstract][Full Text] [Related]
28. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials. Dryden M; Kantecki M; Yan JL; Stone GG; Leister-Tebbe H; Wilcox M J Glob Antimicrob Resist; 2022 Mar; 28():108-114. PubMed ID: 34922058 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559 [TBL] [Abstract][Full Text] [Related]
30. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). Farrell DJ; Flamm RK; Sader HS; Jones RN Int J Antimicrob Agents; 2013 Apr; 41(4):337-42. PubMed ID: 23466338 [TBL] [Abstract][Full Text] [Related]
31. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Frampton JE Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418 [TBL] [Abstract][Full Text] [Related]
32. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149 [TBL] [Abstract][Full Text] [Related]
33. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. Dryden M; Zhang Y; Wilson D; Iaconis JP; Gonzalez J J Antimicrob Chemother; 2016 Dec; 71(12):3575-3584. PubMed ID: 27585969 [TBL] [Abstract][Full Text] [Related]
34. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects. Riccobene TA; Pushkin R; Jandourek A; Knebel W; Khariton T Antimicrob Agents Chemother; 2016 Oct; 60(10):5849-57. PubMed ID: 27431215 [TBL] [Abstract][Full Text] [Related]
35. Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections. Leventogiannis K; Mouktaroudi M; Giamarellos-Bourboulis EJ Curr Opin Infect Dis; 2023 Apr; 36(2):89-94. PubMed ID: 36853762 [TBL] [Abstract][Full Text] [Related]